Skip to main content

Table 2 Univariate analysis of the characteristics associated with miliary TB among TB-IRIS

From: Prevalence and risk factors of paradoxical tuberculosis associated immune reconstitution inflammatory syndrome among HIV-infected patients in Beijing, China

Characteristics Miliary TB (19) N (%) Non-miliary TB (26) N (%) Total (45) N (%) Crude Orb (95% CI) P value
Gender
 Male 18 (94.7) 24 (92.3) 42 (93.3) 1 Ref.
 Female 1 (5.3) 2 (7.7) 3 (6.7) 0.667 (0.056–7.937) 0.748
Age group (years)
  < 25 7 (36.8) 2 (7.7) 9 (20.0) 8.167 (1.412–47.221) 0.019
 25–44 9 (47.4) 21 (80.8) 30 (66.7) 1 Ref.
 45–64 3 (15.8) 2 (7.7) 5 (11.1) 3.500 (0.497–24.654) 0.208
  > 64 0 (0.0) 1 (3.8) 1 (2.2) 1
Initial CD4 cell count
  > 100 1 (5.3) 1 (3.8) 2 (4.4) 1 Ref.
 50–100 1 (5.3) 2 (7.7) 3 (6.7) 0.500 (0.013–19.562) 0.711
  < 50 17 (89.5) 23 (88.5) 40 (88.9) 0.739 (0.043–12.674) 0.835
CD4 cell count after ART
  > 100 6 (31.6) 15 (57.7) 21 (46.7) 1 Ref.
 50–100 8 (42.1) 8 (30.8) 16 (35.5) 2.500 (0.640–9.766) 0.188
  < 50 5 (26.3) 3 (11.5) 8 (17.8) 4.167 (0.749–23.179) 0.103
Increase in CD4 cell count
  < 4 folds 9 (47.4) 12 (46.2) 21 (46.7) 1 Ref.
  ≥ 4 folds 10 (52.6) 14 (53.8) 24 (53.3) 0.952 (0.291–3.117) 0.936
HIV virial load
  ≤ 1000 copies 10 (52.6) 14 (53.8) 24 (53.3) 1 Ref.
  > 1000 copies 9 (47.4) 12 (46.2) 21 (46.7) 1.050 (0.321–3.436) 0.936
HAART regimena
 First-line 15 (78.9) 23 (88.5) 38 (84.4) 1 Ref.
 Second-line 4 (21.1) 3 (11.5) 7 (15.6) 2.044 (0.400–10.457) 0.390
  1. aFirst-line regimen includes tenofovir, lamivudine and efavirenz; Second-line regimen includes tenofovir, lamivudine and lopinavir/ritonavir
  2. bOR, odds ratio; CI, confidential interval